ALTERING THE CLINICAL COURSE OF SORSBY FUNDUS DYSTROPHY WITH THE USE OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INTRAOCULAR THERAPY


    loading  Checking for direct PDF access through Ovid

Abstract

Purpose:Sorsby fundus dystrophy is a rare hereditary condition causing choroidal neovascularization leading to vision loss. Previously, treatment was mostly unsuccessful. Here, we analyze the result of various treatments administered over the years.Methods:Retrospective case-note review.Patients:Three adults from a Spanish family with Sorsby fundus dystrophy showed a very varied course. The untreated case was blind at presentation. Administration of photodynamic therapy and intravitreal anti-vascular endothelial growth factor agents managed to modify the history of disease, more successfully with the latter.Conclusion:The intravitreal administration of anti-vascular endothelial growth factor agents seems to reduce the extent of scarring in Sorsby fundus dystrophy albeit without halting the episodic recurrences. This may lead to improved outcomes even when the visual acuity is compromised.

    loading  Loading Related Articles